Furthermore, while there can be a significant correlation between the methylation of certain genes (i.e., CASP8) and previously described predictive factors for neuroblastoma (i.e., MYCN amplification status) [122]; distinct methylation signatures, such as the so-called CpG island methylator phenotype (CIMP), can independently be associated with clinical prognosis regardless of these other factors [123-125]. The gene discussed is MYCN; the disease is neuroblastoma.